Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, Zetonna, and Alvesco[1] for hay fever in the US and Canada.

Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[2]

It was patented in 1990 and approved for medical use in 2005.[3] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[4] It is on the World Health Organization's List of Essential Medicines.[5]

See also

References

  1. ^ "Covis Pharma – Products".
  2. ^ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–1664. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495.
  4. ^ "FDA News Release. FDA Approves New Treatment for Allergies". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
  5. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

Further reading

  • Rossi S, ed. (2006). Australian Medicines Handbook. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3.